Company: NDRA
Filing Date: 2025-10-28
Form Type: DEF 14A
Source: 0001654954-25-012254
Chunk: 43

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-28
Form: DEF 14A
Chunk 43
---
Michael Harsh

| 32 |

<div align='center'>PROPOSAL 4 - AMENDMENT TO CERTIFICATE OF INCORPORATION TO INCREASE NUMBER OF AUTHORIZED SHARES</div>

The Board of Directors is seeking stockholder approval of an amendment to our Fourth Amended and Restated Certificate of Incorporation (“Certificate of Incorporation”), to increase the number of authorized shares of common stock from 20,000,000 to 1,000,000,000. The proposed Certificate of Amendment to the Certificate of Incorporation (the “Increase in Authorized Shares Certificate of Amendment”) is annexed hereto as Appendix A.

Reasons for the Proposed Increase in Authorized Shares of Common Stock

The Board of Directors believes that the increase in authorized shares of common stock would be beneficial for the following reasons:

| · | Ensuring that an adequate number of shares of common stock are available for potential future corporate purposes. An increase in the number of authorized shares of our common stock enables us to have a sufficient number of shares of common stock available for a variety of possible future corporate purposes, including but not limited to issuing stock under existing equity compensation plans, stock dividends or stock splits, and possible future acquisitions. |
| · | Enabling equity transactions to raise additional capital. The availability of additional shares of our common stock will permit us to raise capital through equity transactions. Any such additional capital may be used to fund the Company’s digital asset treasury operations and the accumulation of cryptocurrency. However, we have no plans, arrangements, or understandings for any such equity transactions at this time.                                           |

The newly authorized shares of common stock would have the same rights as the currently outstanding shares of our common stock. As of October 16, 2025:

| · | 1,166,441 shares of our common stock were issued and outstanding;                                                                                                                              |
| · | 364,801 shares of our common stock were issuable upon the exercise of outstanding prefunded warrants issued in the private placement consummated on October 15, 2025;                          |
| · | 1,669,387 shares of our common stock were issuable upon the exercise of outstanding warrants;                                                                                                  |
| · | 1 share of our common stock were issuable upon the conversion of outstanding shares of Series A Preferred Stock, including shares issuable in respect of accrued and unpaid dividends thereon; |
| · | 266 shares of our common stock were issuable upon the exercise of outstanding stock options issued pursuant to the 2016 Plan